Aflac Incorporated

Q2 FY26Insurance

Aflac Incorporated Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹113

Market cap₹57.3K Cr

P/E13.4

Published29 May 2026

What the Q2 FY26 call signalled

1 of 5 strong

RevenueRank 4

MarginRank 3

CapexYes

FundraiseNo

Order bookNo

The short version

- Japan sales target for 2026 is around JPY 80 billion, slightly higher than 2025’s JPY 74 billion (Dan Amos, Page 12). - Japan's new cancer product and medical product sales showed strong growth in Q1, encouraging outlook for Aflac Japan (Virgil Miller, Page 12). - Aflac Japan expects sales of cancer insurance products in 2026 to be equivalent to 2025, supported by concurrent selling of multiple products (Koichiro Yoshizumi, Page 6). - Japan’s earned premium growth is currently negative 1-2%; flat to modest growth expected when sales reach about JPY 90 billion to offset lapsation (Page 9). - U.S. - Daniel Amos expects Japan sales to be closer to JPY 80 billion in 2026, higher than 2025's JPY 74 billion, indicating growth ambition.

From Aflac Incorporated's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Rank 4

Japan sales target for 2026 is around JPY 80 billion, slightly higher than 2025’s JPY 74 billion (Dan Amos, Page 12).
Japan's new cancer product and medical product sales showed strong growth in Q1, encouraging outlook for Aflac Japan (Virgil Miller, Page 12).
Aflac Japan expects sales of cancer insurance products in 2026 to be equivalent to 2025, supported by concurrent selling of multiple products (Koichiro Yoshizumi, Page 6).
Japan’s earned premium growth is currently negative 1-2%; flat to modest growth expected when sales reach about JPY 90 billion to offset lapsation (Page 9).
U.S. group business sales up 12.4% in Q1; core agent business flat to slightly down but investments underway to boost agent recruitment and productivity (Virgil Miller, Page 8).
U.S. sales increased 2.9% year-over-year in Q1 with strong premium persistency and net earned premium growth of 3.5% (Page 2).

Profitability & Margins

Daniel Amos expects Japan sales to be closer to JPY 80 billion in 2026, higher than 2025's JPY 74 billion, indicating growth ambition.
Earned premium growth in Japan is expected to hover around negative 1% to 2% for the full year, with a midterm strategy focused on new business growth to end stagnation.
U.S. segment shows strong sales growth, with a 2.9% YoY increase and stable benefit ratio guidance of 42%-52% for the full year.
Adjusted Q1 earnings per diluted share increased 6.6% YoY to $1.77 (excluding FX effects), with adjusted ROE at 12.8%.
External reinsurance deals are seen as additive strategies to diversify earnings and grow business with good IRRs, not expected to significantly consume capital or alter shareholder returns.
Despite market challenges, management expects solid profitability and sustained capital deployment to shareholders through dividends and share repurchases.

See what Aflac Incorporated said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Aflac is investing in improving and enhancing its enrollment process to ease onboarding for new agents, helping them sell quickly and be productive early.
The company is investing in innovative products and technology, especially focused on group product offerings catering to smaller employee groups.
External reinsurance deals are pursued as an add-on strategy to grow business and earnings power with good IRRs, diversify earnings streams, and risk profiles without materially consuming capital or affecting shareholder returns.
No current plans to increase leverage; however, there is flexibility to deploy significant capital and liquidity for operations, shareholder returns, or strategic investments like reinsurance deals.
The recent reinsurance transaction with Japan Post Insurance marks a strategic expansion of their reinsurance franchise targeting the Japan market.
Overall, investments focus on methodical growth, evolution rather than revolution, emphasizing capital efficiency and maintaining strong capital ratios.

Fundraising & Capital Structure

Currently, there are no real plans to increase leverage or raise new debt.
The company holds significant capital and liquidity at the holding company to deploy into operations and back to shareholders.
External reinsurance strategies will consume some capital but are expected to be additive and not alter capital deployment to shareholders.
Capital management is flexible and tactical, with strong capital ratios and liquidity ($3.4 billion unencumbered liquidity).
Adjusted leverage stands at 21.2%, within the target range of 20%-25%, influenced by yen-dollar exchange rates as part of a hedging program.
There is ongoing capital deployment through share repurchases ($1 billion) and dividends ($315 million) in Q1.
No mention of equity fundraising or plans for public equity issuance at this time.

See what Aflac Incorporated said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Daniel Amos indicated a target sales figure of around JPY 80 billion for Japan in 2026, higher than 2025's JPY 74 billion, suggesting an expectation of increased orderbook/sales.
Max Broden confirmed JPY 90 billion in sales is needed for flat premium growth in Japan, highlighting that current levels are below that but expected to improve.
Virgil Miller noted strong sales growth in new cancer and medical products in Japan Q1, contributing positively to orderbook.
Aflac Japan has introduced multiple products being sold concurrently, which supports a healthy sales pipeline.
The company maintains a focus on continuing to grow the business methodically, signaling stable pending orders.
No explicit numeric figures on current orderbook or pending orders were disclosed; however, the emphasis on maintaining or increasing sales around JPY 80-90 billion indicates a robust order pipeline.

How does Aflac Incorporated rank vs peers in Insurance?

Pro feature

ThisAflac Incorporated

Rev 4Mar 3

See where Aflac Incorporated sits in InsuranceSee which companies these are, and every other name in the sector.Open rankings

Others in Insurance this season

American Financial Group, Inc. (Q2 FY26)
American Financial Group, Inc. Q2 FY26 quarterly results analysis. Crop insurance gross written premium expected to be flat; net written premiums projected to i
Erie Indemnity Company (Q2 FY26)
Erie Indemnity Company Q2 FY26 quarterly results analysis. Erie expects continued rollout and expansion of Erie Secure Auto into additional states this year, fo
CNA Financial Corporation (Q2 FY26)
CNA Financial Corporation Q2 FY26 quarterly results analysis. Net written premium growth was 1% in Q1 2026, with significant variation by segment and class. Mar
RenaissanceRe Holdings Ltd. (Q2 FY26)
RenaissanceRe Holdings Ltd. Q2 FY26 quarterly results analysis. New demand at midyear renewals is increasing, now estimated closer to $15 billion for U.S. Marke

Compare:vs The Progressive Corporation vs Marsh & McLennan Companies, Inc.vs Aon plc

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aflac Incorporated Q2 FY26 results?

What is Aflac Incorporated share price analysis?

Aflac Incorporated currently shows a neutral. The stock trades at a P/E of 13.4 with a market cap of $57,327. Investors should review the full earnings analysis for detailed insights.

Is Aflac Incorporated planning capital expenditure?

- Aflac is investing in improving and enhancing its enrollment process to ease onboarding for new agents, helping them sell quickly and be productive early.

Keep Aflac Incorporated on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.